ArticleInternational journal of cancer2026
Risk of advanced adenoma detection in colorectal cancer screening programmes according to personal characteristics and screening history.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk of advanced adenoma detection in colorectal cancer screening programmes according to personal characteristics and screening history.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The detection of advanced adenomas (AA) is an important benefit-relevant indicator in colorectal cancer screening programmes (CRCSP). The study hypothesis is that factors related to personal screening history and social characteristics may influence the risk of detecting AA. We performed a retrospective study of men and women aged between 50 and 69 who participated in the Valencia Region CRCSP between 2010 and 2018. Variables: sex, age, number of previous negative faecal occult blood tests (FOBT), and faecal Hb concentration in the previous FOBT (Prev-f-Hb). We analysed the risk of AA and the influence of factors related to screening history in the first screening attendance (First_A) (n = 594,242) and in the most recent screening attendance (Recent_A) (n = 388,558) for people who had participated on at least two occasions. Logistic multivariate models were used to estimate odds ratios (OR). The risk of AA in First_A was higher in men (OR = 2.59; 2.50-2.68) and in the 60-69 age group (OR = 1.62; 1.57-1.67). In Recent_A, the risk was higher in the population with a Prev-f-Hb of greater than 0 ng/mL, and this risk increased for 0.1-19.9 ng/mL, 20-39.9 ng/mL, 40-59.9 ng/mL, 60-79.9 ng/mL, and 80-99.9 ng/mL (women: OR = 1.70, OR = 3.78, OR = 7.05, OR = 9.98, OR = 14.1 and men: OR = 1.66, OR = 3.61, OR = 5.69, OR = 8.45, OR = 10.30, respectively). The risk was lower in the population with four or five previous negative FOBT (OR = 0.76, 0.68-0.85; OR = 0.53, 0.41-0.66). Demographic characteristics and screening history could be used to design risk-adapted screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.